60-70% oncology revenue growth in FY27
Management expects oncology segment to grow 60-70% year-on-year in FY27, building on Q3 FY26's 31 crore quarterly revenue base. 9-month oncology revenue stands at 69.45 crore.
SAKAR / guidance tracker
Keep management guidance in view.
Sakar Healthcare · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
30% EBITDA margin target
As oncology scales up further, management targets EBITDA margins around 30%, up from current 26%, with improved operating leverage and product mix benefits.
Tech transfer portfolio to reach Rs 50-100 crore potential
10 tech transfer molecules from Accord and other partners represent Rs 50-100 crore revenue potential. Second imatinib product already approved; 2 more molecules expected within next 2 months, 3 in following quarter, completing tech transfers by Q1 FY27.
Minimal capex beyond FY26
9-month capex of Rs 39 crore completes planned capacity expansion. Maintenance capex at ~Rs 65 lakh per quarter. No major capex planned for FY27.
~40% revenue growth in FY27
Management expects to sustain ~40% YoY revenue growth in FY27, driven by oncology exports and tech transfers.
Oncology revenue to double to ~₹200 crore in FY27
Oncology revenue expected to double from ~₹96 crore in FY26 to ~₹200 crore in FY27, with exports becoming dominant.
EBITDA margin to sustain ~27-28% and improve
Full-year EBITDA margin of ~27-28% is sustainable and expected to improve as oncology mix increases.
Oncology facility can generate ₹800-1,000 crore at optimal utilization
The Bada oncology facility can potentially generate ₹800-1,000 crore revenue at optimal utilization over 4-5 years without significant incremental capex.